ABSTRACT
Objective To investigate the expression of Pim‐1 in non small cell lung cancer and adjacent normal tissues ,and study the relationship between c‐Myc and Pim‐1 in the corresponding tissue gene expression .Methods Totally 30 cases of non small cell lung cancer tissue and adjacent normal lung tissues were collected by surgical operation in department of thoracic surgery . Clinical data were statisticed and tracking late pathologic results ,using RT‐PCR ,qRT‐PCR and immunohistochemical method to de‐tect Pim‐1 mRNA ,c‐Myc and Pim‐1 protein expression in lung cancer and adjacent normal tissue ,and to analyze the relationship be‐tween the expression of Pim‐1 and c‐Myc .Results The positive rate of Pim‐1 mRNA and protein expression in non small cell lung cancer was obviously higher than that in adjacent normal tissue ,the mRNA expression levels were 0 .798 ± 0 .083 and 0 .394 ± 0 .107 (P0 .05) ,bue had related to ymph node metastasis and TNM stages of tumor (P<0 .05) ,with lymph node metastasis and TNM sta‐ges increases ,its expression quantity also rise .There was a positive correlation between Pim‐1 and c‐Myc protein expression ,corre‐lation coefficient (r) was 0 .433 (P=0 .017) .Conclusion High expression of Pim‐1 in non small cell lung cancer gene and is also increased with lymph node metastasis and TNM stages ,Pim‐1 and c‐Myc expression has positive correlation ,this could provide clues to the early diagnosis and prognosis evaluation of non small cell lung cancer ,and also provides a new train of thought and to find a new target for gene therapy of lung cancer .
ABSTRACT
Objective To evaluate the efficacy of concurrent systemic routine dose of paclitaxel/ cisplatin combined with conventional thoracie irradiation in locally advanced non-small cell lung cancer(NSCLC).Methods Forty-two unresectable stage ⅢA and ⅢB NSCLC patients were entered into this study.All patients received conventional thoracic irradiation to a total dose of 60Gy within 6 weeks,with concurrent paclitaxel 135mg/m~2,d1,and cisplatin 75mg/m~2 in the first and fourth week of radiotherapy.Results The complete response(CR) and partial response(PR) was 2/42,and 30/42 patients,with an overall response rate of 76.2% and a median survival time of 18 months.The 1-,2-,and 3-year survival rate was 64.3%,30.2%,12.0%,respectively.The 1-,2-,and 3-year progression-free survival rates was 48.1%,21.4%,5.7%,with a median progression-free survival of 12 months.Fourteen patients failed only locoregionally,10 in distant metastastasis only and 5 in both.The locoregional/distant failure rate was higher in stageⅢB than in stage ⅢA(P